Literature DB >> 29725522

Survivin as a novel target protein for reducing the proliferation of cancer cells.

Dongyu Li1, Chenghao Hu2, Huibin Li3.   

Abstract

Survivin, also known as baculoviral inhibitor of apoptosis repeat-containing 5, is a novel member of the inhibitor of apoptosis protein family. Survivin is highly expressed in tumors and embryonic tissues and is associated with tumor cell differentiation, proliferation, invasion and metastasis; however, survivin is expressed at low levels in normal terminally differentiated adult tissues. Meanwhile, the expression level of survivin is also a negative prognostic factor for patients with cancer. These unique characteristics of survivin make it an exciting potential therapeutic target for cancer treatment. This review will discuss the biological characteristics of survivin and its potential use as a treatment target to reduce cancer cell proliferation.

Entities:  

Keywords:  cancer; programmed cell death; survivin; target therapy

Year:  2018        PMID： 29725522      PMCID： PMC5920485          DOI： 10.3892/br.2018.1077

Source DB:  PubMed          Journal:  Biomed Rep        ISSN： 2049-9434


  97 in total

1.  Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter.

Authors:  Qiuying Cheng; Xiang Ling; Andrew Haller; Takahito Nakahara; Kentaro Yamanaka; Aya Kita; Hiroshi Koutoku; Masahiro Takeuchi; Michael G Brattain; Fengzhi Li
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

2.  Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection.

Authors:  Takehiko Dohi; Fang Xia; Dario C Altieri
Journal:  Mol Cell       Date:  2007-07-06       Impact factor: 17.970

3.  The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression.

Authors:  F Li; D C Altieri
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

4.  BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery.

Authors:  J Hagenbuchner; A V Kuznetsov; P Obexer; M J Ausserlechner
Journal:  Oncogene       Date:  2012-11-12       Impact factor: 9.867

5.  Rational design of shepherdin, a novel anticancer agent.

Authors:  Janet Plescia; Whitney Salz; Fang Xia; Marzia Pennati; Nadia Zaffaroni; Maria Grazia Daidone; Massimiliano Meli; Takehiko Dohi; Paola Fortugno; Yulia Nefedova; Dmitry I Gabrilovich; Giorgio Colombo; Dario C Altieri
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

6.  Disease recurrence after resection for stage I lung cancer.

Authors:  K al-Kattan; E Sepsas; S W Fountain; E R Townsend
Journal:  Eur J Cardiothorac Surg       Date:  1997-09       Impact factor: 4.191

7.  Identification of cancer stem cells in dog glioblastoma.

Authors:  G Stoica; G Lungu; H Martini-Stoica; S Waghela; J Levine; R Smith
Journal:  Vet Pathol       Date:  2009-01-27       Impact factor: 2.221

Review 8.  Survivin, cancer networks and pathway-directed drug discovery.

Authors:  Dario C Altieri
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

Review 9.  Hsp90: a specialized but essential protein-folding tool.

Authors:  J C Young; I Moarefi; F U Hartl
Journal:  J Cell Biol       Date:  2001-07-23       Impact factor: 10.539

10.  YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

Authors:  Takahito Nakahara; Aya Kita; Kentaro Yamanaka; Masamichi Mori; Nobuaki Amino; Masahiro Takeuchi; Fumiko Tominaga; Shinji Hatakeyama; Isao Kinoyama; Akira Matsuhisa; Masafumi Kudoh; Masao Sasamata
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 13.312
View more
  23 in total

1.  Radionuclide imaging and therapy in malignant melanoma after survivin promoter-directed sodium iodide symporter gene transfer in vitro and in vivo.

Authors:  Zhen Zhao; Rui Huang; Huawei Cai; Bin Liu; Yu Zeng; Anren Kuang
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

Review 2.  Resveratrol as a modulatory of apoptosis and autophagy in cancer therapy.

Authors:  R Yang; H Dong; S Jia; Z Yang
Journal:  Clin Transl Oncol       Date:  2022-01-17       Impact factor: 3.405

3.  Diversity of developing peripheral glia revealed by single-cell RNA sequencing.

Authors:  Ozge E Tasdemir-Yilmaz; Noah R Druckenbrod; Olubusola O Olukoya; Weixiu Dong; Andrea R Yung; Isle Bastille; Maria F Pazyra-Murphy; Austen A Sitko; Evan B Hale; Sébastien Vigneau; Alexander A Gimelbrant; Peter V Kharchenko; Lisa V Goodrich; Rosalind A Segal
Journal:  Dev Cell       Date:  2021-08-31       Impact factor: 13.417

4.  A Highly Effective System for Predicting MHC-II Epitopes With Immunogenicity.

Authors:  Shi Xu; Xiaohua Wang; Caiyi Fei
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

5.  Combination of ERK2 and STAT3 Inhibitors Promotes Anticancer Effects on Acute Lymphoblastic Leukemia Cells.

Authors:  Ewa Jasek-Gajda; Halina Jurkowska; MaŁgorzata JasiŃska; Jan A Litwin; Grzegorz J Lis
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

6.  Dominant-negative ATF5 rapidly depletes survivin in tumor cells.

Authors:  Xiaotian Sun; James M Angelastro; David Merino; Qing Zhou; Markus D Siegelin; Lloyd A Greene
Journal:  Cell Death Dis       Date:  2019-09-24       Impact factor: 8.469

7.  miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib.

Authors:  Leisheng Wang; He En; Lei Yang; Yanbing Zhang; Baisheng Sun; Jianjiang Gao
Journal:  Onco Targets Ther       Date:  2019-08-21       Impact factor: 4.147

Review 8.  Understanding genomics and the immune environment of penile cancer to improve therapy.

Authors:  Ahmet Murat Aydin; Jad Chahoud; Jacob J Adashek; Mounsif Azizi; Anthony Magliocco; Jeffrey S Ross; Andrea Necchi; Philippe E Spiess
Journal:  Nat Rev Urol       Date:  2020-08-18       Impact factor: 14.432

9.  Co-Adjuvant Therapy Efficacy of Catechin and Procyanidin B2 with Docetaxel on Hormone-Related Cancers In Vitro.

Authors:  Mª Jesús Núñez-Iglesias; Silvia Novio; Carlota García; Mª Elena Pérez-Muñuzuri; María-Carmen Martínez; José-Luis Santiago; Susana Boso; Pilar Gago; Manuel Freire-Garabal
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

Review 10.  Functional Compartmentalization of HSP60-Survivin Interaction between Mitochondria and Cytosol in Cancer Cells.

Authors:  Ya-Hui Huang; Chau-Ting Yeh
Journal:  Cells       Date:  2019-12-19       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.